Coming up behind the mRNA leaders, Sanofi, GSK pivot into PhI/II trial for their traditional tech approach to a Covid-19 vaccine. This race isn't over yet
Right now all eyes are on a pair of cutting-edge mRNA vaccines currently cruising through fast Phase III Covid-19 trials with a shot at delivering pivotal, and likely quite controversial, data in October. But as promised, Sanofi and GSK — with a big assist from the US government — are launching a Phase I/II study for another vaccine that relies on some reassuringly tried-and-true technology on display in the annual flu shot.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.